MedTrace Logo

Ultrasound Guided Diuretic Therapy in Type 1 Cardiorenal Syndrome

NCT06065163 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-10-05

No results posted yet for this study

Summary

A double-blind, randomized, controlled trial was conducted with the main objective of evaluating if patients with clinical assessment and VExUS reach decongestion faster within a maximum period of 7 days during the hospital stay. Likewise, the study will describe those patients who experience a decrease in serum creatinine (CrS), NT-proBNP at discharge, greater diuretic adjustment, rate of intrahospital readmission, and 30-day mortality.

Conditions

  • Cardiorenal Syndrome Type 1

Interventions

OTHER

Diuretic de/escalation based on ultrasound findings (VExUS Score)

Patients allocated in the experimental arm will have diuretic dosing adjusted based on ultrasound findings (VExUS Score)

OTHER

Diuretic de/escalation based on clinical findings (CCS Score)

Patients allocated in the experimental arm will have diuretic dosing adjusted based on clinical findings (CCS Score)

Sponsors & Collaborators

  • EchoNous Inc.

    collaborator INDUSTRY

  • Instituto Nacional de Cardiologia Ignacio Chavez

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06065163 on ClinicalTrials.gov